Safety of lopinavir/ritonavir for the treatment of HIV-infection.

about

Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics.

P2860

Q37866298-50164E33-5527-4F50-B4AB-9A524C729423

P2860

Safety of lopinavir/ritonavir for the treatment of HIV-infection.

Item

http://www.wikidata.org/entity/Q36150530

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Safety of lopinavir/ritonavir for the treatment of HIV-infection.

@ast

Safety of lopinavir/ritonavir for the treatment of HIV-infection.

@en

type

Item

label

Safety of lopinavir/ritonavir for the treatment of HIV-infection.

@ast

Safety of lopinavir/ritonavir for the treatment of HIV-infection.

@en

prefLabel

Safety of lopinavir/ritonavir for the treatment of HIV-infection.

@ast

Safety of lopinavir/ritonavir for the treatment of HIV-infection.

@en

P1476

Safety of lopinavir/ritonavir for the treatment of HIV-infection.

@en

P2093

Martin Vogel

http://www.w3.org/2001/XMLSchema#string

P2860

Rational design of peptide-based HIV proteinase inhibitors

Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir.

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy.

Decline in the AIDS and death rates in the EuroSIDA study: an observational study.

Adverse effects of antiretroviral therapy.

Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study.

Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.

The metabolic effects of lopinavir/ritonavir in HIV-negative men

Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor.

Protease inhibitor-sparing simplified maintenance therapy: a need for perspective.

P304

403-420

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14740338.4.3.403

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jürgen Rockstroh

P577

2005-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15934849

http://www.w3.org/2001/XMLSchema#string

Safety of lopinavir/ritonavir for the treatment of HIV-infection.

about

P2860

P2860

Safety of lopinavir/ritonavir for the treatment of HIV-infection.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698